Simultaneous quantification of dasatinib, nilotinib, bosutinib, and ponatinib using high‐performance liquid chromatography–Photodiode array detection

BACKGROUND: Dasatinib, nilotinib, and bosutinib, second‐generation tyrosine kinase inhibitors (TKIs), and ponatinib, a third‐generation TKI, are approved pharmaceuticals used in the treatment of chronic myeloid leukemia (CML). Although liquid chromatography‐tandem mass spectrometry assays for simult...

Descripción completa

Detalles Bibliográficos
Autores principales: Yokoyama, Yuta, Nozawa, Eiji, Morita, Miho, Ishikawa, Emi, Mori, Takehiko, Sakurai, Masatoshi, Kikuchi, Taku, Matsuki, Eri, Yamazaki, Rie, Kataoka, Keisuke, Jibiki, Aya, Kawazoe, Hitoshi, Suzuki, Sayo, Nakamura, Tomonori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396206/
https://www.ncbi.nlm.nih.gov/pubmed/35819095
http://dx.doi.org/10.1002/jcla.24598

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396206/
https://www.ncbi.nlm.nih.gov/pubmed/35819095
http://dx.doi.org/10.1002/jcla.24598

Ejemplares similares